Skip to main content
Clinical Trials/NCT03525301
NCT03525301
Unknown
N/A

SHort Course Accelerated RadiatiON Therapy (SHARON) in Palliative Treatment of Brain Metastases: an Interventional, Randomised, Multicentric Study

IRCCS Azienda Ospedaliero-Universitaria di Bologna1 site in 1 country108 target enrollmentNovember 8, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Brain Metastases
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
108
Locations
1
Primary Endpoint
Efficacy of palliation using the short course scheme compared with the standard scheme
Last Updated
7 years ago

Overview

Brief Summary

Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic brain metastases from solid tumors

Detailed Description

Standard treatment for brain metastases (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (1800 cGy in 4 fractions of 450 cGy twice a day) to demonstrate non-inferiority of this scheme

Registry
clinicaltrials.gov
Start Date
November 8, 2017
End Date
November 8, 2023
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Alessio Giuseppe Morganti

Professor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Eligibility Criteria

Inclusion Criteria

  • symptomatic brain metastases from solid tumors
  • age \> 18 years
  • ECOG performance status 0-3
  • no changes in supportive care in the week before radiotherapy

Exclusion Criteria

  • pregnancy
  • previous irradiation of the same region

Outcomes

Primary Outcomes

Efficacy of palliation using the short course scheme compared with the standard scheme

Time Frame: 3 months

Reduction of initial symptoms after radiotherapy, assessed with Likert scale (weakness, motor disorders, cognitive impairment, personality changes, loss of balance, seizures, changes in speech, vision, hearing, memory problems, nausea or vomiting are evaluated as none-mild-moderate-severe)

Secondary Outcomes

  • Acute toxicity in the two treatment groups(3 months)
  • Late toxicity in the two treatment groups(12 months)
  • Quality of Life (QoL) assessment in the two groups(12 months)

Study Sites (1)

Loading locations...

Similar Trials